R-CHOP/Ibrutinib Alternating with R-DHAX Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen that alternates rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and ibrutinib with rituximab, dexamethasone, high-dose cytarabine and oxaliplatin (R-DHAX) that can be used for the treatment of mantle cell lymphoma (MCL).

**Synonyms:** - Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine Plus Ibrutinib Alternating with Rituximab Plus Cytarabine/Dexamethasone/Oxaliplatin - Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine/Ibrutinib-Rituximab/Cytarabine/Dexamethasone/Oxaliplatin - IR-CHOP/R-DHAOx - IR-CHOP/R-DHAOx (rituximab-abbs) - IR-CHOP/R-DHAOx (rituximab-arrx) - IR-CHOP/R-DHAOx (rituximab-blit) - IR-CHOP/R-DHAOx (rituximab-pvvr) - IR-CHOP/R-DHAOx (rituximab-rite) - IR-CHOP/R-DHAOx (rituximab-rixa) - IR-CHOP/R-DHAOx (rituximab-rixi) - R-CHOP-Ibrutinib Alternating with R-DHAX - R-CHOP-Ibrutinib/R-DHAX - R-CHOP-Ibrutinib/R-DHAX Regimen